期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 3, 期 2, 页码 197-212出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200800154
关键词
ICAT; iTRAQ; MRM; SELDI-TOF-MS; SILAC; SRM
资金
- PROMET [FP6-LSH-5-2004-018858]
- P-MARK [LSHC-CT-2004-503011]
- EU
- Engineering and Physical Sciences Research Council (EPSRC) [EP/E036252/1, GR/S84347/01]
- MRC-DTA [G0501392]
- EPSRC [EP/E036252/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [EP/E036252/1, GR/S84347/01] Funding Source: researchfish
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer-related deaths in men. Currently, serum prostate-specific antigen (PSA) is the only biomarker widely used in the diagnosis and management of patients with PCa. However, PSA lacks diagnostic sensitivity and specificity leading to false-negative and false-positive test results. PSA cannot distinguish indolent from aggressive disease, leading to many patients being over-treated with associated side-effects. Further-more, PSA is unable to identify which tumors are likely to become unresponsive to treatment at an early stage. Thus, there is an urgent need for clinically validated biomarkers which will improve the diagnosis and management of PCa. Given the heterogeneity of PCa it is likely that a panel of biomarkers will be required. in the quest for PCa biomarkers, a wide range of samples including urine, serum, tissues, and cell lines have been studied using proteomic approaches such as 2-DE, SELDI-TOF, SILAC, ICAT, iTRAQ, and MALDI-IMS. The value of these technologies, and other emerging platforms such as selected reaction monitoring (SRM) and multiple reaction monitoring (MRM), are discussed in the context of biomarker discovery, validation and addressing the bottle-necks that exist prior to clinical translation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据